ArticleAnnals of hematology2026
In-hospital mortality and complications are increased in hematopoietic stem cell transplant recipients with myelodysplastic syndromes.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative therapy for patients with myelodysplastic syndromes (MDS). Despite evidence of comparable outcomes in selected older adults, disparities in HSCT utilization persist. This study analyzes trends, outcomes, and barriers such as age and insurance status associated with HSCT in MDS. We performed a retrospective analysis of the National Inpatient Sample (NIS) from 2016 to 2020 using ICD-10 codes to identify adult patients undergoing allogeneic HSCT. Patients were stratified according to MDS diagnosis. National estimates were calculated using discharge weights. Baseline characteristics and outcomes were compared using Pearson Chi-square and t-tests. Propensity score matching was used to adjust for potential confounders. Among 30,460 patients who underwent allogeneic HSCT, 4,980 (16.16%) had MDS. MDS patients were older (median age 62 vs. 49 years, p<0.001) and had a higher burden of comorbidities, including chronic lung disease, diabetes, and hypertension (p<0.001). They were more likely to be insured through Medicare (38.73% vs. 17.10%) and less likely to have private insurance (50.80% vs. 56.96%, p<0.001). From 2016 to 2020, the proportion of HSCT performed in patients with MDS increased from 13.20% to 17.32% before a slight decline in 2020. MDS patients experienced in-hospital mortality (aOR 1.33, 95% CI 1.14-1.55), mechanical ventilation (aOR 1.30), neutropenic fever (aOR 1.20), and acute GVHD (aOR 1.26), but lower Clostridium difficile infection (aOR 0.75). MDS patients undergoing allogeneic HSCT are older, carry greater comorbidity burdens, and have worse in-hospital outcomes. Insurance disparities and age may continue to represent barriers despite increasing utilization. Further research is needed to optimize selection and peri-transplant care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.